ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1164

Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis

Paul Bird 1, Mikael Boesen 2, Mark Hinton 3, Eser Sanverdi 3, Romiesa Hagoug 3, Chrisotpher Sabin 3, Priscila Nakasato 4, Benoit Guerette 4 and Olga Kubassova5, 1Optimus Research, Kogarah, New South Wales, Australia, 2Dept. of Radiology, Copenhagen University Hospital Bispebjerg-Frederiksberg, Copenhagen, Denmark, Copenhagen, Denmark, 3Image Analysis Ltd, London, United Kingdom, 4Celgene Corporation, Summit, 5Image Analysis Group, London, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Magnetic resonance imaging (MRI), Psoriatic arthritis, Synovitis, tendonitis/bursitis and wrist

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Imaging Of Rheumatic Diseases Poster II

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Response to treatment in Psoriatic Arthritis (PsA) can be captured using the OMERACT PsA Magnetic Resonance Imaging Score (PsAMRIS). While reliable and valid, PsAMRIS interpretation requires a trained reader to assess inflammatory lesions on a discrete scale ranging from 0 to 3 and gives decrease values of changes which might not capture subtle changes in inflammation in small cohorts. In this study, we propose a novel computer-assisted imaging quantitative methodology to assess early response to treatment on a continuous scale and validate it by comparing its results with PsAMRIS synovitis scores.

Methods: 114 patients were treated with Apremilast 30mg BID, after a 5-day titration period. Patients had MRI scans at baseline, month 3 and 6. Given the need to rapidly assess the impact of new therapies on imaging structures, PsAMRIS responses were compared to those of a new novel computer-assisted quantitative method at 3 months. Images at baseline and 3 months were scored for synovitis using the PSAMRIS interpreted by an experienced reader and were read in blinded sequences. Images at baseline, 3 and 6 months were further processed using a novel computer-assisted quantitative method. At a pixel level, each pixel’s intensity in the joint was normalized to the intensity of a reference region (muscle). A heat map of normalized intensities was produced, highlighting areas of perfusion higher than that of healthy muscle (NormI), as shown in Figure 1. An experienced reader pre-defined regions of interest (ROIs) around the wrist and the metacarpophalangeal joint (MCP) joints. From these ROIs, the volume of inflammation was calculated in each joint and tendon. This was done by counting pixels that were enhanced above the intensity level of the normal muscle. Each enhanced pixel was given a weight corresponding to the degree of enhancement, allowing to differentiate areas of residual inflammation and high perfusion. This method has been validated, tested and implemented in the CE/FDA510 cleared software package Dynamika (IAG, Image Analysis Group). Patients with non-missing data were included in the final statistical analysis.

Results: IIn all cases a downward trend was observed at 3 months, indicating a reduction in inflammatory activity under treatment with Apremilast. At 3 months the NormI wrist score showed a reduction of 12% compared with the PsAMRIS synovitis score that reduced by 2%. Similar NormI results were observed for the MCPs and tendons (Figure 2). Results suggested continuous improvements over time, with reductions of 16.5% in the wrist, 0.9% in the MCPs and 16.7% in the tendons.

Conclusion: Computer assisted methodology has been developed to assess inflammation in patients with PsA and shown to be more responsive to changes in synovitis than the PsAMRIS at 3 months. Both methods demonstrated reduction of inflammation. This novel method could be used to provide early indications of treatment response. Further validation with larger datasets is planned.

Figure 1: MRI scans and NormI maps superimposed on MRIs for a PsA patient imaged at baseline, Month 3 and 6.

Figure 2. From the top: the mean values of NormI for the wrist, MCP and tendon at baseline, 3 and 6 months, showing reduction in inflammatory activity.


Disclosure: P. Bird, Pfizer, 5, AbbVie, 5, Novartis, 5, Janssen, 5, Celgene, 5, Eli Lilly, 5; M. Boesen, Image Analysis LTD, 1, UCB, 5, Abbvie, 5, Eli Lilly, 5, Novartis, 5, Glenmark, 5, Pfizer, 5, Astra Zeneca, 5, Esaote, 9; M. Hinton, Image Analysis Limited, 3; E. Sanverdi, Image Analysis Limited, 3; R. Hagoug, Image Analysis Limited, 3; C. Sabin, Image Analysis Limited, 3; P. Nakasato, Celgene Corporation, 3; B. Guerette, Celgene Corporation, 3; O. Kubassova, Image Analysis Group, 1, 3, 4.

To cite this abstract in AMA style:

Bird P, Boesen M, Hinton M, Sanverdi E, Hagoug R, Sabin C, Nakasato P, Guerette B, Kubassova O. Novel Computer Assisted Methodology for Quantitative Assessment of MRI Treatment Responses to Apremilast in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/novel-computer-assisted-methodology-for-quantitative-assessment-of-mri-treatment-responses-to-apremilast-in-patients-with-psoriatic-arthritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/novel-computer-assisted-methodology-for-quantitative-assessment-of-mri-treatment-responses-to-apremilast-in-patients-with-psoriatic-arthritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology